Premium
BeiGene Ltd (BGNE)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system ... BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world. Show more
Vote recommends a class-wide PD-L1 expression level cut-off across PD-1 inhibitors in advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction cancers Biologics License...
（ビジネスワイヤ） -- がん領域におけるグローバル企業であるベイジーン（NASDAQ：BGNE、HKEX：06160、SSE：688235）は、2024年9月27日付で、シャリニ・シャープを同社の役員および取締役会監査役に任命したこ...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), ein globales Onkologieunternehmen, gab heute die Ernennung von Shalini Sharp in sein Board of Directors und zum Mitglied des...
BeiGene, Ltd. (NASDAQ : BGNE ; HKEX : 06160 ; SSE : 688235), société internationale d'oncologie, a annoncé aujourd'hui la nomination de Shalini Sharp à son conseil d'administration et comme...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Shalini Sharp to its Board of Directors and as a member of the Board’s Audit...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Israeli Ministry of Health (IL MOH) has approved TEVIMBRA® (tislelizumab) as...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), uma empresa global de Oncologia, anuncia hoje a aprovação do TEVIMBRA® (tislelizumab) pela Agência Nacional de Vigilância Sanitária (ANVISA). Este...
Ergebnisse von RATIONALE-315, 307 und 305 unterstützen den Nutzen des PD-1-Inhibitors TEVIMBRA (Tislelizumab) bei nicht-kleinzelligem Lungenkrebs und Magenkrebs/Gastroösophagus-Krebs BeiGene...
BeiGene, Ltd. (NASDAQ : BGNE ; HKEX : 06160 ; SSE : 688235), une société internationale spécialisée en oncologie, a annoncé aujourd'hui la nomination de Matt Shaulis au poste de directeur général...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
